GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProMIS Neurosciences Inc (FRA:23J0) » Definitions » EV-to-FCF

ProMIS Neurosciences (FRA:23J0) EV-to-FCF : -0.46 (As of Dec. 12, 2024)


View and export this data going back to 2017. Start your Free Trial

What is ProMIS Neurosciences EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, ProMIS Neurosciences's Enterprise Value is €9.32 Mil. ProMIS Neurosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was €-20.32 Mil. Therefore, ProMIS Neurosciences's EV-to-FCF for today is -0.46.

The historical rank and industry rank for ProMIS Neurosciences's EV-to-FCF or its related term are showing as below:

FRA:23J0' s EV-to-FCF Range Over the Past 10 Years
Min: -17.01   Med: -4.17   Max: 0.29
Current: -0.52

During the past 13 years, the highest EV-to-FCF of ProMIS Neurosciences was 0.29. The lowest was -17.01. And the median was -4.17.

FRA:23J0's EV-to-FCF is ranked worse than
100% of 386 companies
in the Biotechnology industry
Industry Median: 8.605 vs FRA:23J0: -0.52

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-12), ProMIS Neurosciences's stock price is €0.94. ProMIS Neurosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was €-0.191. Therefore, ProMIS Neurosciences's PE Ratio (TTM) for today is At Loss.


ProMIS Neurosciences EV-to-FCF Historical Data

The historical data trend for ProMIS Neurosciences's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProMIS Neurosciences EV-to-FCF Chart

ProMIS Neurosciences Annual Data
Trend Mar14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.58 -6.62 -3.88 -1.84 -0.84

ProMIS Neurosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.70 -0.84 -1.81 -1.53 -0.87

Competitive Comparison of ProMIS Neurosciences's EV-to-FCF

For the Biotechnology subindustry, ProMIS Neurosciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProMIS Neurosciences's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProMIS Neurosciences's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where ProMIS Neurosciences's EV-to-FCF falls into.



ProMIS Neurosciences EV-to-FCF Calculation

ProMIS Neurosciences's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=9.317/-20.323
=-0.46

ProMIS Neurosciences's current Enterprise Value is €9.32 Mil.
ProMIS Neurosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-20.32 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ProMIS Neurosciences  (FRA:23J0) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

ProMIS Neurosciences's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.94/-0.191
=At Loss

ProMIS Neurosciences's share price for today is €0.94.
ProMIS Neurosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.191.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


ProMIS Neurosciences EV-to-FCF Related Terms

Thank you for viewing the detailed overview of ProMIS Neurosciences's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


ProMIS Neurosciences Business Description

Traded in Other Exchanges
Address
1920 Yonge Street, Suite 200, Toronto, ON, CAN, M4S 3E2
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

ProMIS Neurosciences Headlines

No Headlines